<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35113871</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Low-level overexpression of wild type TDP-43 causes late-onset, progressive neurodegeneration and paralysis in mice.</ArticleTitle><Pagination><StartPage>e0255710</StartPage><MedlinePgn>e0255710</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0255710</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0255710</ELocationID><Abstract><AbstractText>Modestly increased expression of transactive response DNA binding protein (TDP-43) gene have been reported in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neuromuscular diseases. However, whether this modest elevation triggers neurodegeneration is not known. Although high levels of TDP-43 overexpression have been modeled in mice and shown to cause early death, models with low-level overexpression that mimic the human condition have not been established. In this study, transgenic mice overexpressing wild type TDP-43 at less than 60% above the endogenous CNS levels were constructed, and their phenotypes analyzed by a variety of techniques, including biochemical, molecular, histological, behavioral techniques and electromyography. The TDP-43 transgene was expressed in neurons, astrocytes, and oligodendrocytes in the cortex and predominantly in astrocytes and oligodendrocytes in the spinal cord. The mice developed a reproducible progressive weakness ending in paralysis in mid-life. Detailed analysis showed ~30% loss of large pyramidal neurons in the layer V motor cortex; in the spinal cord, severe demyelination was accompanied by oligodendrocyte injury, protein aggregation, astrogliosis and microgliosis, and elevation of neuroinflammation. Surprisingly, there was no loss of lower motor neurons in the lumbar spinal cord despite the complete paralysis of the hindlimbs. However, denervation was detected at the neuromuscular junction. These results demonstrate that low-level TDP-43 overexpression can cause diverse aspects of ALS, including late-onset and progressive motor dysfunction, neuroinflammation, and neurodegeneration. Our findings suggest that persistent modest elevations in TDP-43 expression can lead to ALS and other neurological disorders involving TDP-43 proteinopathy. Because of the predictable and progressive clinical paralytic phenotype, this transgenic mouse model will be useful in preclinical trial of therapeutics targeting neurological disorders associated with elevated levels of TDP-43.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chunxing</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Transgenics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hongyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yansu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salameh</LastName><ForeName>Johnny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metterville</LastName><ForeName>Jake</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parsi</LastName><ForeName>Sepideh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yusuf</LastName><ForeName>Issa</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>RNA Therapeutic Institute, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Program, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Huaibin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Transgenics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zuoshang</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-1209-334X</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>RNA Therapeutic Institute, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Program, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS111990</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG000946</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1 NS068391</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS101895</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS092127</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS062230</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AG000946</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS118145</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>3</Day><Hour>17</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35113871</ArticleId><ArticleId IdType="pmc">PMC8812852</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0255710</ArticleId><ArticleId IdType="pii">PONE-D-21-23627</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162&#x2013;72. doi: 10.1056/NEJMra1603471 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al.. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al.. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;11. Epub 2006/11/07. S0006-291X(06)02318-7 [pii] doi: 10.1016/j.bbrc.2006.10.093 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al.. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;3. doi: 10.1126/science.1134108 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9(10):995&#x2013;1007. doi: 10.1016/S1474-4422(10)70195-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70195-2</ArticleId><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Yang C. TDP-43&#x2014;The key to understanding amyotrophic lateral sclerosis. Rare Diseases. 2014;2(1):e944443. doi: 10.4161/21675511.2014.944443</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/21675511.2014.944443</ArticleId><ArticleId IdType="pmc">PMC4755248</ArticleId><ArticleId IdType="pubmed">26942097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416&#x2013;38. doi: 10.1016/j.neuron.2013.07.033 ; PubMed Central PMCID: PMC4411085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinchetti P, Rizzuti M, Faravelli I, Corti S. MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis. Mol Neurobiol. 2018;55(3):2617&#x2013;30. doi: 10.1007/s12035-017-0537-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0537-z</ArticleId><ArticleId IdType="pubmed">28421535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349(6248):650&#x2013;5. doi: 10.1126/science.aab0983 ; PubMed Central PMCID: PMC4825810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton CF, Good SK, Atkin S, Dewey CM, Mayer P, Herz J, et al.. TDP-43 is a developmentally-regulated protein essential for early embryonic development. Journal of Biological Chemistry. 2009;285(9):6826&#x2013;34. doi: 10.1074/jbc.M109.061846</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.061846</ArticleId><ArticleId IdType="pmc">PMC2825476</ArticleId><ArticleId IdType="pubmed">20040602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer BC, Schuck T, Wheeler JM, Robinson LC, Trojanowski JQ, Lee VM, et al.. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 2010;119(4):409&#x2013;19. doi: 10.1007/s00401-010-0659-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0659-0</ArticleId><ArticleId IdType="pmc">PMC2880609</ArticleId><ArticleId IdType="pubmed">20198480</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L-S, Cheng W-C, Hou S-C, Yan Y-T, Jiang S-T, Shen CKJ. TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis. genesis. 2010;48(1):56&#x2013;62. doi: 10.1002/dvg.20584</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvg.20584</ArticleId><ArticleId IdType="pubmed">20014337</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang P-M, Ling J, Jeong YH, Price DL, Aja SM, Wong PC. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proceedings of the National Academy of Sciences. 2010;107(37):16320&#x2013;4. doi: 10.1073/pnas.1002176107</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1002176107</ArticleId><ArticleId IdType="pmc">PMC2941284</ArticleId><ArticleId IdType="pubmed">20660762</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al.. TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis. Science. 2008;319(5870):1668&#x2013;72. doi: 10.1126/science.1154584</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Velde CV, et al.. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40(5):572&#x2013;4. doi: 10.1038/ng.132</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Functional Significance of TDP-43 Mutations in Disease. Adv Genet. 2015;91:1&#x2013;53. doi: 10.1016/bs.adgen.2015.07.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.adgen.2015.07.001</ArticleId><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 Is Intrinsically Aggregation-prone, and Amyotrophic Lateral Sclerosis-linked Mutations Accelerate Aggregation and Increase Toxicity. J Biol Chem. 2009;284(30):20329&#x2013;39. doi: 10.1074/jbc.M109.010264</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.010264</ArticleId><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini M, Romano V, Avendano-Vazquez SE, Bembich S, Buratti E, Baralle FE. Role of selected mutations in the Q/N rich region of TDP-43 in EGFP-12xQ/N-induced aggregate formation. Brain Res. 2012;1462:139&#x2013;50. doi: 10.1016/j.brainres.2012.02.031 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.02.031</ArticleId><ArticleId IdType="pubmed">22406069</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Kaneko K, Yamanaka K. Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins. J Biol Chem. 2013;288(5):3641&#x2013;54. doi: 10.1074/jbc.M112.433615 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.433615</ArticleId><ArticleId IdType="pmc">PMC3561582</ArticleId><ArticleId IdType="pubmed">23235148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentmann E, Neumann M, Tahirovic S, Rodde R, Dormann D, Haass C. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43). J Biol Chem. 2012;287(27):23079&#x2013;94. doi: 10.1074/jbc.M111.328757 ; PubMed Central PMCID: PMC3391091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.328757</ArticleId><ArticleId IdType="pmc">PMC3391091</ArticleId><ArticleId IdType="pubmed">22563080</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald KK, Aulas A, Destroismaisons L, Pickles S, Beleac E, Camu W, et al.. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum Mol Genet. 2011;20(7):1400&#x2013;10. doi: 10.1093/hmg/ddr021 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr021</ArticleId><ArticleId IdType="pubmed">21257637</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VMY, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci. 2011;13(1):38&#x2013;50. doi: 10.1038/nrn3121</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3121</ArticleId><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Arai K, Del Tredici K, Toledo JB, Robinson JL, Lee EB, et al.. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol. 2014;128(3):423&#x2013;37. doi: 10.1007/s00401-014-1299-6 ; PubMed Central PMCID: PMC4384652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1299-6</ArticleId><ArticleId IdType="pmc">PMC4384652</ArticleId><ArticleId IdType="pubmed">24916269</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al.. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20&#x2013;38. doi: 10.1002/ana.23937 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday G, Bigio E, Cairns N, Neumann M, Mackenzie IA, Mann DA. Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. Acta Neuropathologica. 2012;124(3):373&#x2013;82. doi: 10.1007/s00401-012-1030-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1030-4</ArticleId><ArticleId IdType="pmc">PMC3445027</ArticleId><ArticleId IdType="pubmed">22878865</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu ZS. Does a loss of TDP-43 function cause neurodegeneration? Mol Neurodegener. 2012;7:27. doi: 10.1186/1750-1326-7-27 ; PubMed Central PMCID: PMC3419078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-27</ArticleId><ArticleId IdType="pmc">PMC3419078</ArticleId><ArticleId IdType="pubmed">22697423</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, Geser F, Plotkin JB, Clark CM, Kwong LK, Yuan W, et al.. Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. Hum Mol Genet. 2008;17(10):1349&#x2013;62. doi: 10.1093/hmg/ddn023 ; PubMed Central PMCID: PMC2900863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn023</ArticleId><ArticleId IdType="pmc">PMC2900863</ArticleId><ArticleId IdType="pubmed">18223198</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Phaneuf D, Dupre N, Petri S, Strong M, Kriz J, et al.. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. J Exp Med. 2011;208(12):2429&#x2013;47. doi: 10.1084/jem.20111313 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra M, Paunesku T, Woloschak GE, Siddique T, Zhu LJ, Lin S, et al.. Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. Acta Neuropathol. 2007;114(1):81&#x2013;94. doi: 10.1007/s00401-007-0240-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0240-7</ArticleId><ArticleId IdType="pubmed">17569064</ArticleId></ArticleIdList></Reference><Reference><Citation>Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, et al.. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2008;79(10):1186&#x2013;9. doi: 10.1136/jnnp.2007.131334</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2007.131334</ArticleId><ArticleId IdType="pmc">PMC2586594</ArticleId><ArticleId IdType="pubmed">18796596</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Albuquerque CP, Han JS, Lagier-Tourenne C, Tokunaga S, Zhou H, et al.. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci U S A. 2010;107(30):13318&#x2013;23. doi: 10.1073/pnas.1008227107 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1008227107</ArticleId><ArticleId IdType="pmc">PMC2922163</ArticleId><ArticleId IdType="pubmed">20624952</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho M, Bigio E, Mishra M, Johnson N, Weintraub S, Mesulam M, et al.. TARDBP 3&#x2019;-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathologica. 2009;118(5):633&#x2013;45. doi: 10.1007/s00401-009-0571-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0571-7</ArticleId><ArticleId IdType="pmc">PMC2783457</ArticleId><ArticleId IdType="pubmed">19618195</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin JA, Wright GS, Watanabe S, Grossmann JG, Antonyuk SV, Yamanaka K, et al.. Disease causing mutants of TDP-43 nucleic acid binding domains are resistant to aggregation and have increased stability and half-life. Proc Natl Acad Sci U S A. 2014;111(11):4309&#x2013;14. doi: 10.1073/pnas.1317317111 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1317317111</ArticleId><ArticleId IdType="pmc">PMC3964094</ArticleId><ArticleId IdType="pubmed">24591609</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilican B, Serio A, Barmada SJ, Nishimura AL, Sullivan GJ, Carrasco M, et al.. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A. 2012;109(15):5803&#x2013;8. doi: 10.1073/pnas.1202922109 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1202922109</ArticleId><ArticleId IdType="pmc">PMC3326463</ArticleId><ArticleId IdType="pubmed">22451909</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Kim E, Duffy A, Adalbert R, Phillips BU, Peters OM, et al.. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21(4):552&#x2013;63. doi: 10.1038/s41593-018-0113-5 ; PubMed Central PMCID: PMC5884423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Rothstein JD. Rodent Models of Amyotrophic Lateral Sclerosis. Curr Protoc Pharmacol. 2015;69:5 67 1&#x2013;5 21. doi: 10.1002/0471141755.ph0567s69 ; PubMed Central PMCID: PMC4562058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471141755.ph0567s69</ArticleId><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JC, Constable R, So E, Vance C, Scotter E, Glover L, et al.. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. Acta Neuropathol Commun. 2015;3:36. doi: 10.1186/s40478-015-0212-4 ; PubMed Central PMCID: PMC4479086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0212-4</ArticleId><ArticleId IdType="pmc">PMC4479086</ArticleId><ArticleId IdType="pubmed">26108367</ArticleId></ArticleIdList></Reference><Reference><Citation>Stribl C, Samara A, Trumbach D, Peis R, Neumann M, Fuchs H, et al.. Mitochondrial dysfunction and decrease in body weight of a transgenic knock-in mouse model for TDP-43. J Biol Chem. 2014;289(15):10769&#x2013;84. doi: 10.1074/jbc.M113.515940 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.515940</ArticleId><ArticleId IdType="pmc">PMC4036193</ArticleId><ArticleId IdType="pubmed">24515116</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Sivakumar P, Humphrey J, Lo K, Ricketts T, Oliveira H, et al.. Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO J. 2018;37(11). doi: 10.15252/embj.201798684 ; PubMed Central PMCID: PMC5983119.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798684</ArticleId><ArticleId IdType="pmc">PMC5983119</ArticleId><ArticleId IdType="pubmed">29764981</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishino K, Watanabe S, Shijie J, Murata Y, Oiwa K, Komine O, et al.. Mice deficient in the C-terminal domain of TAR DNA-binding protein 43 develop age-dependent motor dysfunction associated with impaired Notch1-Akt signaling pathway. Acta Neuropathol Commun. 2019;7(1):118. doi: 10.1186/s40478-019-0776-5 ; PubMed Central PMCID: PMC6657153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0776-5</ArticleId><ArticleId IdType="pmc">PMC6657153</ArticleId><ArticleId IdType="pubmed">31345270</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon D, Dafinca R, Scaber J, Alegre-Abarrategui J, Farrimond L, Scott C, et al.. Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction. Neurobiol Dis. 2019;121:148&#x2013;62. doi: 10.1016/j.nbd.2018.09.024 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.09.024</ArticleId><ArticleId IdType="pubmed">30290270</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebstein SY, Yagudayeva I, Shneider NA. Mutant TDP-43 Causes Early-Stage Dose-Dependent Motor Neuron Degeneration in a TARDBP Knockin Mouse Model of ALS. Cell Rep. 2019;26(2):364&#x2013;73 e4. doi: 10.1016/j.celrep.2018.12.045 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.12.045</ArticleId><ArticleId IdType="pubmed">30625319</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitsky T, et al.. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal. 1996;13(6):159&#x2013;63. doi: 10.1016/s1050-3862(96)00167-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1050-3862(96)00167-2</ArticleId><ArticleId IdType="pubmed">9117892</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Danielson EW, Qiao T, Metterville J, Brown RH Jr., Landers JE, et al.. Mutant PFN1 causes ALS phenotypes and progressive motor neuron degeneration in mice by a gain of toxicity. Proc Natl Acad Sci U S A. 2016. doi: 10.1073/pnas.1605964113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1605964113</ArticleId><ArticleId IdType="pmc">PMC5068285</ArticleId><ArticleId IdType="pubmed">27681617</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Wang H, Qiao T, Yang B, Aliaga L, Qiu L, et al.. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2014;111(12):E1121&#x2013;9. doi: 10.1073/pnas.1322641111 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1322641111</ArticleId><ArticleId IdType="pmc">PMC3970502</ArticleId><ArticleId IdType="pubmed">24616503</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini M, Buratti E. TDP-43 autoregulation: implications for disease. J Mol Neurosci. 2011;45(3):473&#x2013;9. doi: 10.1007/s12031-011-9573-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9573-8</ArticleId><ArticleId IdType="pubmed">21681666</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al.. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14(4):459&#x2013;68. Epub 2011/03/02. nn.2779 [pii] doi: 10.1038/nn.2779 ; PubMed Central PMCID: PMC3094729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, et al.. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14(4):452&#x2013;8. doi: 10.1038/nn.2778 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2778</ArticleId><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener. 2020;15(1):45. doi: 10.1186/s13024-020-00397-1 ; PubMed Central PMCID: PMC7429473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Varas R, Ortiz FC. Neuroinflammation in Demyelinating Diseases: Oxidative Stress as a Modulator of Glial Cross-Talk. Curr Pharm Des. 2019;25(45):4755&#x2013;62. doi: 10.2174/1381612825666191216125725 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612825666191216125725</ArticleId><ArticleId IdType="pubmed">31840603</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong L, Lee E, Kremmer E, Flatley A, Xu Y, et al.. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathologica. 2009. doi: 10.1007/s00401-008-0477-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0477-9</ArticleId><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Lu S, Yu H, Chen C, Melamed Z, Guo L, et al.. Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death. Neuron. 2019;102(2):339&#x2013;57 e7. doi: 10.1016/j.neuron.2019.02.038 ; PubMed Central PMCID: PMC6548321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.02.038</ArticleId><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B. The Evolution of Phase-Separated TDP-43 in Stress. Neuron. 2019;102(2):265&#x2013;7. doi: 10.1016/j.neuron.2019.03.041 ; PubMed Central PMCID: PMC6816464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.03.041</ArticleId><ArticleId IdType="pmc">PMC6816464</ArticleId><ArticleId IdType="pubmed">30998893</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, et al.. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proceedings of the National Academy of Sciences. 2010;107(8):3858&#x2013;63. doi: 10.1073/pnas.0912417107</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912417107</ArticleId><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings NR, Puttaparthi K, Luther CM, Burns DK, Elliott JL. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol Dis. 2010;40(2):404&#x2013;14. doi: 10.1016/j.nbd.2010.06.017 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.06.017</ArticleId><ArticleId IdType="pubmed">20621187</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, Ling SC, Huelga SC, Lagier-Tourenne C, Polymenidou M, Ditsworth D, et al.. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A. 2013;110(8):E736&#x2013;45. doi: 10.1073/pnas.1222809110 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Wang Q, Zhang K, An T, Shi P, Li Z, et al.. HO-1 induction in motor cortex and intestinal dysfunction in TDP-43 A315T transgenic mice. Brain Res. 2012;1460:88&#x2013;95. doi: 10.1016/j.brainres.2012.04.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.04.003</ArticleId><ArticleId IdType="pubmed">22578468</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella R, Capitini C, Fani G, Dobson CM, Cecchi C, Chiti F. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies. J Biol Chem. 2016;291(37):19437&#x2013;48. doi: 10.1074/jbc.M116.737726 ; PubMed Central PMCID: PMC5016682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.737726</ArticleId><ArticleId IdType="pmc">PMC5016682</ArticleId><ArticleId IdType="pubmed">27445339</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohan Z, Matej R, Rusina R, Kovacs GG. Oligodendroglial response in the spinal cord in TDP-43 proteinopathy with motor neuron involvement. Neurodegener Dis. 2013;14(3):117&#x2013;24. doi: 10.1159/000362929 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000362929</ArticleId><ArticleId IdType="pubmed">25115814</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Truax AC, Vanmassenhove B, Kretzschmar HA, Van Deerlin VM, et al.. TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol. 2007;66(3):177&#x2013;83. doi: 10.1097/01.jnen.0000248554.45456.58 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000248554.45456.58</ArticleId><ArticleId IdType="pubmed">17356379</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama A, Sugai A, Kato T, Ishihara T, Shiga A, Toyoshima Y, et al.. Increased cytoplasmic TARDBP mRNA in affected spinal motor neurons in ALS caused by abnormal autoregulation of TDP-43. Nucleic Acids Res. 2016;44(12):5820&#x2013;36. doi: 10.1093/nar/gkw499 ; PubMed Central PMCID: PMC4937342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw499</ArticleId><ArticleId IdType="pmc">PMC4937342</ArticleId><ArticleId IdType="pubmed">27257061</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L-S, Cheng W-C, Shen CK. Targeted Depletion of TDP-43 Expression in the Spinal Cord Motor Neurons Leads to the Development of Amyotrophic Lateral Sclerosis (ALS)-like Phenotypes in Mice. Journal of Biological Chemistry. 2012. doi: 10.1074/jbc.M112.359000</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.359000</ArticleId><ArticleId IdType="pmc">PMC3431639</ArticleId><ArticleId IdType="pubmed">22718760</ArticleId></ArticleIdList></Reference><Reference><Citation>Donde A, Sun M, Ling JP, Braunstein KE, Pang B, Wen X, et al.. Splicing repression is a major function of TDP-43 in motor neurons. Acta Neuropathol. 2019;138(5):813&#x2013;26. doi: 10.1007/s00401-019-02042-8 ; PubMed Central PMCID: PMC6802294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02042-8</ArticleId><ArticleId IdType="pmc">PMC6802294</ArticleId><ArticleId IdType="pubmed">31332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. The Journal of Cell Biology. 2009;187(6):761&#x2013;72. doi: 10.1083/jcb.200908164</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200908164</ArticleId><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al.. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312(5778):1389&#x2013;92. doi: 10.1126/science.1123511 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, et al.. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2006;103(43):16021&#x2013;6. doi: 10.1073/pnas.0607423103 ; PubMed Central PMCID: PMC1613228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0607423103</ArticleId><ArticleId IdType="pmc">PMC1613228</ArticleId><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, et al.. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11(3):251&#x2013;3. doi: 10.1038/nn2047 ; PubMed Central PMCID: PMC3137510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2047</ArticleId><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SH, Fukaya M, Yang JK, Rothstein JD, Bergles DE. NG2+ CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. Neuron. 2010;68(4):668&#x2013;81. doi: 10.1016/j.neuron.2010.09.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.09.009</ArticleId><ArticleId IdType="pmc">PMC2989827</ArticleId><ArticleId IdType="pubmed">21092857</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadeas ST, Kraig SE, O&#x2019;Banion C, Lepore AC, Maragakis NJ. Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo. Proc Natl Acad Sci U S A. 2011;108(43):17803&#x2013;8. doi: 10.1073/pnas.1103141108 ; PubMed Central PMCID: PMC3203804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1103141108</ArticleId><ArticleId IdType="pmc">PMC3203804</ArticleId><ArticleId IdType="pubmed">21969586</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci. 2007;10(5):608&#x2013;14. doi: 10.1038/nn1885 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1885</ArticleId><ArticleId IdType="pmc">PMC3139463</ArticleId><ArticleId IdType="pubmed">17435754</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, et al.. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10(5):615&#x2013;22. doi: 10.1038/nn1876 ; PubMed Central PMCID: PMC3799799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1876</ArticleId><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol. 2012;237(1):147&#x2013;52. doi: 10.1016/j.expneurol.2012.06.011 ; PubMed Central PMCID: PMC4126417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.06.011</ArticleId><ArticleId IdType="pmc">PMC4126417</ArticleId><ArticleId IdType="pubmed">22735487</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Tong J, Bi F, Zhou H, Xia XG. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J Clin Invest. 2012;122(1):107&#x2013;18. doi: 10.1172/JCI59130 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI59130</ArticleId><ArticleId IdType="pmc">PMC3248298</ArticleId><ArticleId IdType="pubmed">22156203</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong J, Huang C, Bi F, Wu Q, Huang B, Liu X, et al.. Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. Embo J. 2013;32(13):1917&#x2013;26. doi: 10.1038/emboj.2013.122 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2013.122</ArticleId><ArticleId IdType="pmc">PMC3981181</ArticleId><ArticleId IdType="pubmed">23714777</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips AM, Gross SK, Williams T, Tuteja A, Sherman A, Ko M, et al.. Altered astrocytic expression of TDP-43 does not influence motor neuron survival. Exp Neurol. 2013;250:250&#x2013;9. doi: 10.1016/j.expneurol.2013.10.004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2013.10.004</ArticleId><ArticleId IdType="pubmed">24120466</ArticleId></ArticleIdList></Reference><Reference><Citation>Serio A, Bilican B, Barmada SJ, Ando DM, Zhao C, Siller R, et al.. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc Natl Acad Sci U S A. 2013;110(12):4697&#x2013;702. doi: 10.1073/pnas.1300398110 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1300398110</ArticleId><ArticleId IdType="pmc">PMC3607024</ArticleId><ArticleId IdType="pubmed">23401527</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeili MA, Panahi M, Yadav S, Hennings L, Kiaei M. Premature death of TDP-43 (A315T) transgenic mice due to gastrointestinal complications prior to development of full neurological symptoms of amyotrophic lateral sclerosis. Int J Exp Pathol. 2013;94(1):56&#x2013;64. doi: 10.1111/iep.12006 ; PubMed Central PMCID: PMC3575874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iep.12006</ArticleId><ArticleId IdType="pmc">PMC3575874</ArticleId><ArticleId IdType="pubmed">23317354</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzipetros T, Bogdanik LP, Tassinari VR, Kidd JD, Moreno AJ, Davis C, et al.. C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Res. 2014;1584:59&#x2013;72. doi: 10.1016/j.brainres.2013.10.013 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2013.10.013</ArticleId><ArticleId IdType="pubmed">24141148</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J, Wils H, Kleinberger G, Joris G, Cuijt I, Ceuterick-de Groote C, et al.. Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Mol Neurobiol. 2013;48(1):22&#x2013;35. doi: 10.1007/s12035-013-8427-5 ; PubMed Central PMCID: PMC3718993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8427-5</ArticleId><ArticleId IdType="pmc">PMC3718993</ArticleId><ArticleId IdType="pubmed">23475610</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>